Gökhan Metan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3677085/publications.pdf

Version: 2024-02-01

65

all docs

361413 1,677 62 20 citations h-index papers

65

g-index 65 2727 docs citations times ranked citing authors

289244

40

#	Article	IF	CITATIONS
1	Disseminated Brucella melitensis infection following canakinumab treatment. Travel Medicine and Infectious Disease, 2022, 45, 102227.	3.0	2
2	Do antimicrobial stewardship programs improve the quality of care in ICU patients diagnosed with infectious diseases following consultation? Experience in a tertiary care hospital. International Journal of Infectious Diseases, 2022, 115, 201-207.	3.3	4
3	Vorikonazol Terapötik İlaç Düzeyi İzlemi: Bir Üniversite Hastanesi Deneyimi. Flora: the Journal of Infectious Diseses and Clinical Microbiology = Infeksiyon Hastalıkları Ve Klinik Mikrobiyoloji Dergisi, 2022, 27, 183-188.	0.1	1
4	Sensitivity Affected by Disease Severity and Serum Sampling Time: a Performance Evaluation of Six SARS-CoV-2 Antibody Immunoassays. Japanese Journal of Infectious Diseases, 2022, 75, 388-394.	1.2	1
5	Is there still a room for improvement in antimicrobial use in a setting where use of broad-spectrum antibiotics require approval of an infectious diseases physician?. Infection Control and Hospital Epidemiology, 2022, , 1-3.	1.8	0
6	The guideline compatibility of mucormycosis management: A retrospective review of 165 case reports from European quality (EQUAL) score perspective. Journal De Mycologie Medicale, 2022, 32, 101308.	1.5	1
7	Thirty-day readmission rate of COVID-19 patients discharged from a tertiary care university hospital in Turkey: an observational, single-center study. International Journal for Quality in Health Care, 2021, 33, .	1.8	29
8	Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turkish Journal of Medical Sciences, 2021, 51, 411-420.	0.9	14
9	Is COVID-19 a risk factor for invasive pulmonary aspergillosis in critically ill patients?. Tuberkuloz Ve Toraks, 2021, 69, 118-120.	0.4	2
10	Human Ace D/I Polymorphism Could Affect the Clinicobiological Course of COVID-19. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2021, 2021, 1-7.	1.7	20
11	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. Journal of Infectious Diseases, 2020, 221, 356-366.	4.0	17
12	Emergence of colistin and carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (CCR-Acb) complex in a neurological intensive care unit followed by successful control of the outbreak. Journal of Infection and Public Health, 2020, 13, 564-570.	4.1	13
13	Structural Properties and Performance Test Standards of Surgical Masks with Respirators Used in Healthcare Settings. Flora: the Journal of Infectious Diseses and Clinical Microbiology = Infeksiyon Hastalıkları Ve Klinik Mikrobiyoloji Dergisi, 2020, 25, 292-300.	0.1	O
14	Out-patient management of patients with COVID-19 on home isolation. Infezioni in Medicina, 2020, 28, 351-356.	1.1	5
15	Performance of Galactomannan Antigen, Beta-d-Glucan, and Aspergillus-Lateral-Flow Device for the Diagnosis of Invasive Aspergillosis. Indian Journal of Hematology and Blood Transfusion, 2017, 33, 87-92.	0.6	15
16	Is surveillance for colonization of carbapenem-resistant gram-negative bacteria important in adult bone marrow transplantation units?. American Journal of Infection Control, 2017, 45, 735-739.	2.3	25
17	A Silent Epidemic of Colistin- and Carbapenem-Resistant Enterobacteriaceae at a Turkish University Hospital. Infection Control and Hospital Epidemiology, 2017, 38, 254-257.	1.8	5
18	Cessation of Contact Precautions for Extended-Spectrum Beta-Lactamase (ESBL)–Producing ⟨i⟩Escherichia coli⟨ i⟩ Seems to be Safe in a Nonepidemic Setting. Infection Control and Hospital Epidemiology, 2017, 38, 1379-1381.	1.8	2

#	Article	IF	CITATIONS
19	A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre. Infezioni in Medicina, 2017, 25, 33-37.	1.1	4
20	Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups. Current Opinion in Infectious Diseases, 2016, 29, 555-560.	3.1	9
21	Surveillance for Ventilator-Associated Pneumonia: Can We Apply Centers for Disease Control and Prevention–National Healthcare Safety Network 2013 Definitions for All Settings?. Infection Control and Hospital Epidemiology, 2016, 37, 1125-1127.	1.8	2
22	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09â€related pneumonia: an individual participant data metaâ€analysis. Influenza and Other Respiratory Viruses, 2016, 10, 192-204.	3.4	54
23	Bacterial factors influencing the mortality for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteremia. Infectious Diseases, 2016, 48, 649-650.	2.8	1
24	Does antimicrobial usage before meningitis lead to a higher risk of adult postsurgical Acinetobacter baumannii meningitis than that of Enterobacteriaceae meningitis?. Infezioni in Medicina, 2016, 24, 293-298.	1.1	1
25	Natural cutaneous anthrax infection, but not vaccination, induces a CD4+ T cell response involving diverse cytokines. Cell and Bioscience, 2015, 5, 20.	4.8	7
26	<i>Saprochaete capitata</i> as an emerging fungus among patients with haematological malignencies. Mycoses, 2015, 58, 491-497.	4.0	23
27	A Single Center Experience for Antifungal Prophylaxis in Patients with Acute Myelogenous Leukemia. Indian Journal of Hematology and Blood Transfusion, 2015, 31, 339-345.	0.6	3
28	Tigecycline for the treatment of <i>Clostridium difficile </i> infection refractory to metronidazole in haematopoietic stem cell transplant recipients. Journal of Chemotherapy, 2015, 27, 354-357.	1.5	8
29	Anthrax Lethal Factor as an Immune Target in Humans and Transgenic Mice and the Impact of HLA Polymorphism on CD4+ T Cell Immunity. PLoS Pathogens, 2014, 10, e1004085.	4.7	18
30	Do We Really Need Ribavirin in the Treatment of Crimean-Congo Hemorrhagic Fever?. Journal of Chemotherapy, 2014, 26, 146-149.	1.5	8
31	Carbapenem-resistant <i>Klebsiella pneumoniae</i> sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination. Journal of Chemotherapy, 2014, 26, 276-281.	1.5	24
32	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respiratory Medicine, the, 2014, 2, 395-404.	10.7	527
33	A nightmare for haematology clinics: extensively drug-resistant (XDR) Acinetobacter baumannnii. Infezioni in Medicina, 2014, 22, 277-82.	1.1	6
34	What is the role of the (1â†'3)â€î²â€dâ€glucan assay in the screening of patients undergoing autologous haematopoietic stemâ€cell transplantation?. Mycoses, 2013, 56, 34-38.	4.0	16
35	Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology–oncology patients. International Journal of Hematology, 2013, 97, 414-420.	1.6	25
36	Clonal diversity and high prevalence of OXA-58 among Acinetobacter baumannii isolates from blood cultures in a tertiary care centre in Turkey. Infection, Genetics and Evolution, 2013, 14, 92-97.	2.3	18

#	Article	IF	CITATIONS
37	Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia: a retrospective analysis of 154 cases. Brazilian Journal of Infectious Diseases, 2013, 17, 143-149.	0.6	34
38	Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?. Journal of Chemotherapy, 2013, 25, 286-291.	1.5	3
39	Clinical presentations and diagnosis of brucellosis. Recent Patents on Anti-infective Drug Discovery, 2013, 8, 34-41.	0.8	34
40	What should be the optimal cut-off of serum $1,3-\hat{l}^2$ -d-glucan for the detection of invasive pulmonary aspergillosis in patients with haematological malignancies?. Scandinavian Journal of Infectious Diseases, 2012, 44, 330-336.	1.5	20
41	Comment on "Frequency of Epitope-Specific Naive CD4+ T Cells Correlates with Immunodominance in the Human Memory Repertoireâ€, Journal of Immunology, 2012, 188, 5205-5206.	0.8	1
42	Intravitreal tigecycline treatment in experimental Acinetobacter baumannii endophthalmitis. Journal of Chemotherapy, 2012, 24, 101-106.	1.5	11
43	Can bacteraemia lead to false positive results in 1,3-beta-d-glucan test? Analysis of 83 bacteraemia episodes in high-risk patients for invasive fungal infections. Revista Iberoamericana De Micologia, 2012, 29, 169-171.	0.9	22
44	Does ampicillinâ€sulbactam cause false positivity of (1,3)â€betaâ€Dâ€glucan assay? A prospective evaluation of 15 patients without invasive fungal infections*. Mycoses, 2012, 55, 366-371.	4.0	23
45	Bradycardia in a patient with Crimean-Congo hemorrhagic fever related to ribavirin treatment. Journal of Vector Borne Diseases, 2012, 49, 193-4.	0.4	6
46	Hospitalized pandemic influenza A (H1N1) patients in a university hospital. Open Medicine (Poland), 2011, 6, 83-88.	1.3	1
47	A case of Crimean-Congo haemorrhagic fever successfully treated with therapeutic plasma exchange and ribavirin. Tropical Doctor, 2011, 41, 181-182.	0.5	12
48	Pneumocystis jiroveci pneumonia (PCP) misdiagnosed as pandemic influenza H1N1 in a renal transplant patient. Infezioni in Medicina, 2011, 19, 182-4.	1.1	4
49	Natural Exposure to Cutaneous Anthrax Gives Long-Lasting T Cell Immunity Encompassing Infection-Specific Epitopes. Journal of Immunology, 2010, 184, 3814-3821.	0.8	45
50	A review of cutaneous anthrax and its outcome. Journal of Infection and Public Health, 2010, 3, 98-105.	4.1	90
51	Neurobrucellosis: an evaluation of a rare presentation of brucellosis from a tertiary care centre in Central Anatolia, Turkey. Tropical Doctor, 2009, 39, 233-235.	0.5	5
52	Human Anthrax in Turkey from 1990 to 2007. Vector-Borne and Zoonotic Diseases, 2009, 9, 131-140.	1.5	46
53	Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. European Journal of Internal Medicine, 2009, 20, 540-544.	2.2	70
54	Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. International Journal of Antimicrobial Agents, 2008, 31, 523-526.	2.5	129

#	Article	IF	CITATION
55	Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. Journal of Antimicrobial Chemotherapy, 2007, 60, 197-199.	3.0	68
56	CTX-M-3-type extended-spectrum $\hat{1}^2$ -lactamase-producing Morganella morganii: first description of an isolate from Turkey. International Journal of Antimicrobial Agents, 2007, 30, 368-370.	2.5	2
57	Brucellosis in all patients with febrile neutropenia. Leukemia and Lymphoma, 2006, 47, 954-956.	1.3	6
58	Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Scandinavian Journal of Infectious Diseases, 2006, 38, 527-531.	1.5	47
59	Impact of Initial Antimicrobial Therapy in Patients with Bloodstream Infections Caused by Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy, 2005, 49, 3980-3981.	3.2	28
60	False positivity for Aspergillus antigenemia related to the administration of piperacillin/tazobactam. European Journal of Internal Medicine, 2005, 16, 489-491.	2.2	22
61	Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum β-lactamase-producing. International Journal of Antimicrobial Agents, 2005, 26, 254-257.	2.5	32
62	First Confirmed Cases of 2019 Novel Coronavirus in a University Hospital in Turkey: Housemate Internists. Acta Medica, 0, , 1-7.	0.2	0